Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 134900
Corporate User License Price USD 6000
Corporate User License Price INR 404700
Site License Price USD 4000
Site License Price INR 269800
Request a Quote

Report Title

Rotavirus Infections-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Rotavirus Infections-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Rotavirus Infections-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Rotavirus Infections-Pipeline Review, H1 2017



Executive Summary

Rotavirus Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections-Pipeline Review, H1 2017, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape.

Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rotavirus Infections-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 4 and 1 molecules, respectively.

Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Rotavirus Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Rotavirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Rotavirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Rotavirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Rotavirus Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Rotavirus Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Rotavirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rotavirus Infections-Overview

Rotavirus Infections-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rotavirus Infections-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rotavirus Infections-Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech International Ltd

Biological E Ltd

Curevac AG

Medicago Inc

Nanotherapeutics Inc

Serum Institute of India Ltd

Shantha Biotechnics Ltd

Takeda Pharmaceutical Company Ltd

Wuhan Institute of Biological Products Co Ltd

Rotavirus Infections-Drug Profiles

Rotavac-5C-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus (tetravalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus (virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus (virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus (virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [Serotype P2-VP8] (monovalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [Serotype P2] (trivalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus [serotypes G1, G2, G3, G4] (tetravalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RV-3BB-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RV-625-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus Infections-Dormant Projects

Rotavirus Infections-Product Development Milestones

Featured News & Press Releases

Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus

Oct 14, 2014: Shantha`s Investigational Rotavirus Vaccine Enters Phase III Clinical Trials in India

Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate

Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus

Apr 26, 2012: GSK's Rotarix To Be Introduced In Ghana

Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan

May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Rotavirus Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Rotavirus Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Rotavirus Infections-Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017

Rotavirus Infections-Pipeline by Bharat Biotech International Ltd, H1 2017

Rotavirus Infections-Pipeline by Biological E Ltd, H1 2017

Rotavirus Infections-Pipeline by Curevac AG, H1 2017

Rotavirus Infections-Pipeline by Medicago Inc, H1 2017

Rotavirus Infections-Pipeline by Nanotherapeutics Inc, H1 2017

Rotavirus Infections-Pipeline by Serum Institute of India Ltd, H1 2017

Rotavirus Infections-Pipeline by Shantha Biotechnics Ltd, H1 2017

Rotavirus Infections-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Rotavirus Infections-Pipeline by Wuhan Institute of Biological Products Co Ltd, H1 2017

Rotavirus Infections-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Beijing Minhai Biotechnology Co Ltd, Bharat Biotech International Ltd, Biological E Ltd, Curevac AG, Medicago Inc, Nanotherapeutics Inc, Serum Institute of India Ltd, Shantha Biotechnics Ltd, Takeda Pharmaceutical Company Ltd, Wuhan Institute of Biological Products Co Ltd

Rotavirus Infections Therapeutic Products under Development, Key Players in Rotavirus Infections Therapeutics, Rotavirus Infections Pipeline Overview, Rotavirus Infections Pipeline, Rotavirus Infections Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand